Weasel, December PR stated evaluation of critic
Post# of 148112
(Total Views: 661)
Posted On: 01/25/2022 5:45:11 AM
Weasel,
December PR stated evaluation of critical patients after 51 patients.
CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022
DSMB to meet after 15 patients to evaluate safety of Leronlimab
https://www.cytodyn.com/investors/news-events...odify-cd16
December PR stated evaluation of critical patients after 51 patients.
CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022
DSMB to meet after 15 patients to evaluate safety of Leronlimab
https://www.cytodyn.com/investors/news-events...odify-cd16
Quote:
Does anybody remember how many critical patients we now need official for interim analysis in brazil?
I am somewhere lost in Naders usual assumptions/ could be/ should be / "we will ask ANVISA" talk.
If I can remember correctly, the last number was around 75 critical patients in the brazil trial, followed by some talk about resizing the trial, meta analysis with CD12, US trial and reduction to <30 critical patients required for interim (?).
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼